Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 21;51(2):1701815.
doi: 10.1183/13993003.01815-2017. Print 2018 Feb.

Sarcoidosis mortality in Sweden: a population-based cohort study

Marios Rossides  1 , Susanna Kullberg  2   3   4 , Johan Askling  5   6 , Anders Eklund  2   3   4 , Johan Grunewald  2   3   4 , Elizabeth V Arkema  5
Affiliations

Sarcoidosis mortality in Sweden: a population-based cohort study

Marios Rossides et al. Eur Respir J. .

Abstract

We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity.Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In a subset, cases receiving treatment ±3 months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status.The mortality rate was 11.0 per 1000 person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000 person-years). The HR for death was 1.61 (95% CI 1.47‒1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3 months, the HR was 1.13 (95% CI 0.94‒1.35). The HR was 2.34 (95% CI 1.99‒2.75) for those receiving treatment.Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Figures

FIGURE 1
FIGURE 1
Adjusted survival functions of individuals with incident sarcoidosis and general population comparators a) overall and b) by age at inclusion.
FIGURE 2
FIGURE 2
Adjusted survival functions of individuals with incident sarcoidosis compared to the general population, stratified by treatment status.
See this image and copyright information in PMC

References

    1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736–755. - PubMed
    1. Arkema EV, Grunewald J, Kullberg S, et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016; 48: 1690–1699. - PubMed
    1. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis 1990; 7: 50–57. - PubMed
    1. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183: 1524–1530. - PMC - PubMed
    1. Duncan ME, Goldacre MJ. Mortality trends for tuberculosis and sarcoidosis in English populations, 1979–2008. Int J Tuberc Lung Dis 2012; 16: 38–42. - PubMed

Publication types

LinkOut - more resources